Grifols (GRFS) Non-Current Debt (2010 - 2025)
Grifols (GRFS) reported Non-Current Debt of $10.6 billion for Q4 2025, up 4.34% on a YoY basis from $10.1 billion in Q4 2024, and up 4.34% quarter-over-quarter from $10.1 billion in Q4 2024.
Grifols (GRFS) Non-Current Debt (2010 - 2025) Analysis & Trends
Grifols has reported Non-Current Debt for 16 years, with the latest figure at $10.6 billion in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Debt rose 4.34% year-over-year to $10.6 billion; the trailing twelve-month figure through Dec 2025 stood at $10.6 billion (up 4.34% YoY), and the FY2025 full-year result was $10.6 billion, up 4.34% from the prior year.
- Non-Current Debt for Q4 2025 stood at $10.6 billion, up from $10.1 billion in the prior quarter.
- The five-year high for Non-Current Debt was $10.6 billion in Q4 2025, with the low at $875.9 million in Q4 2023.
- Historically, Non-Current Debt has averaged $8.2 billion across 5 years, with a median of $10.1 billion in 2024.
- Annual changes were most pronounced in 2023 — Non-Current Debt sank 91.48% — and 2024, when it soared 1057.91%.
- Grifols' Non-Current Debt stood at $8.9 billion in 2021, then climbed by 15.65% to $10.3 billion in 2022, then slumped by 91.48% to $875.9 million in 2023, then soared by 1057.91% to $10.1 billion in 2024, then rose by 4.34% to $10.6 billion in 2025.
- The last three Non-Current Debt figures came in at $10.6 billion (Q4 2025), $10.1 billion (Q4 2024), and $875.9 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -18.89 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 39.37 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 37.53 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 64.53 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 46.67 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 51.89 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 20.86 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 60.57 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 42.15 Bn |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - | 10.58 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.58 Bn |
| Dec 31, 2025 | 10.58 Bn |
| Dec 31, 2024 | 10.14 Bn |
| Dec 31, 2024 | 10.14 Bn |
| Dec 31, 2023 | 875.89 Mn |
| Dec 31, 2023 | 875.89 Mn |
| Dec 31, 2022 | 10.28 Bn |
| Dec 31, 2022 | 10.28 Bn |
| Dec 31, 2021 | 8.89 Bn |
| Dec 31, 2021 | 8.89 Bn |
| Dec 31, 2020 | 7.87 Bn |
| Dec 31, 2020 | 7.87 Bn |
| Sep 30, 2020 | 7.86 Bn |
| Sep 30, 2020 | 7.86 Bn |
| Mar 31, 2020 | 7.58 Bn |
| Mar 31, 2020 | 7.58 Bn |
| Dec 31, 2019 | 66.39 Mn |
| Dec 31, 2019 | 66.39 Mn |
| Sep 30, 2019 | 7.68 Bn |
| Sep 30, 2019 | 7.68 Bn |